PROM1 and metastatic malignant neoplasm in the lymph nodes: The role for CD133 as a prognostic marker in breast cancer was firstly demonstrated by Liu et al., who revealed that high PROM1 expression in invasive ductal carcinoma positively correlates with adverse clinic-pathological factors, as tumor size and lymph node metastasis [22].